Ecem Yigit

Radiation Oncologist

[Ankara Büyükşehir @ankarabbld]

📣 DUYURU

[Dominik Wawrzuta @WawrzutaD]

Can a single word influence cancer treatment preferences?

In our randomized experiment, calling the same treatment “radiotherapy” rather than “radiation therapy” increased preference for radiation treatment by 8.3 percentage points.

Just published in @IJROBP: https://t.co/mFmlAuccCc

With @KatLudwikowska & @JustynaKlejdysz

[Ecem Yigit @EcemYigitMD]

📄 Full text available here:
https://t.co/y2GoASKahZ

[Ecem Yigit @EcemYigitMD]

🔎 Does uterine position matter during cervical cancer brachytherapy?

Happy to share our new publication! 🌸

🔹 Retroversion → ⬆️ rectal & bowel doses
🔹 Anteversion → ⬆️ target doses
🔹 Similar oncologic outcomes, but more late G1–2 GI adverse events with retroversion

[ESTRO @ESTRO_RT]

💡 #Oligometastatic highlights from #ESTRO26:
🔹 Prostate: RADIOSA: SBRT + 6mo ADT cuts metast. progression risk by 61%
🔹 GynOnc: MITO RT3/RAD: SBRT safe 1–12mo post-bevacizumab
🔹 Lung: Single-fraction SABR: 90% 2-yr local control
👉 https://t.co/khxTiKPj5Y
#RadOnc

[Giulio Francolini @GiulioFrancoli1]

Excited to share the results of the #ARTO trial. After a median f-up of 53 months, Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55). @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT
https://t.co/SpNaZHIByX

[ASTRO @ASTRO_org]

New today in #PracticalRO: Joint guideline from ASTRO, ASCO & SSO on post-mastectomy radiation therapy for patients with breast cancer. Updated recommendations cover indications, dosing, fractionation & multidisciplinary techniques. #RadOnc #BreastCancer
https://t.co/fH5P9vorPU

@ASCO @SocSurgOnc

[David Palma, MD, PhD @drdavidpalma]

Check out the SUNSET dosimetry study in @IJROBP.
Key findings:

- 73% treated without PTV compromise
- PTV compromise not associated with local control
- More overlap with central structures worse local control

- Remember: IV contrast + 4D CT required, 5 mm PTV margins, hotspot 120% or less.

[ASTRO @ASTRO_org]

Read a new #RedJournal article from @mtugceyilmaz et al on 15 Years of Experience with Stereotactic Body Radiotherapy for Recurrent Head and Neck Cancers: A Detailed Analysis of Patients with Carotid Blowout Syndrome. https://t.co/cAVRLPNZDr

[Melek Tugce Yilmaz MD @mtugceyilmaz]

🚨 Just out in Red Journal!

We analyzed our 191-patient H&N reirradiation cohort, with a specific focus on toxicity and CBOS

📊 Real-world SBRT data
🧑‍⚕️ Lessons on patient selection & risk mitigation

https://t.co/cOEDvumhdY

@IJROBP @YaziciYazicig @kahvecioglu_a @EcemYigitMD

[Alper Kahvecioglu MD @kahvecioglu_a]

Honored to have our abstract on intravitreal melatonin for radiation retinopathy ranked among the top 5% at #ESTRO25 !

Proud of our team and grateful for the recognition 🙏🏻

Let’s keep advancing radiation oncology! @ESTRO_RT @EcemYigitMD @zorlu_faruk

[Pervin Hurmuz @PervinHurmuz]

#ESTRO2025 was an amazing meeting with lots of impressive presentations, good science and great networking! Thank you ESTRO! @hcemonal @alison_tree @BarbaraJereczek @kahvecioglu_a @EcemYigitMD

[Enrique Grande @drenriquegrande]

⚡️ New multicenter data on SBRT for primary renal cell carcinoma (RCC):

- 98% LC at 1 year, 96% at 5 years

- Median OS: 58 months

- Preserved renal function & low severe toxicity

A promising noninvasive option for inoperable RCC

#KidneyCancer #Oncology @_S@_ShankarSiva @dr_alimuhammad @UliSchick @stephane_supiot @CiroFranzese1 @MartaScorsetti
@DrAndreiFodor @NicosiaMd @alongi_filippo @MarioTerlizziFR @PBlanchardMD @BaudeJeremy
@mcmbarthoulot @David__Pasquier

https://t.co/r69E9J8bmC

[ESTRO @ESTRO_RT]

Diagnosis and Treatment of Radiation Induced Pneumonitis in Patients with #LungCancer, an ESTRO clinical practice #guideline just published in the @RO_GreenJournal
👉 https://t.co/YhimJMBzTT #radonc

[IJGC @IJGConline]

#EditorsChoice Notable surgical trials in gynecologic oncology: a 10-year overview

🔍 https://t.co/xbakd9hCey

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @claritasantia @RParejaGineOnco

[Arif Akyildiz @Arif_Akyildiz_]

Our recent study, which revealed that a cisplatin dose of >200 mg improved survival in cervical cancer patients receiving CRT, has been published.@OncoAlert @Hasancagri_y https://t.co/vXzu1wpJrq

[Ecem Yigit @EcemYigitMD]

@kahvecioglu_a @drdavidpalma Treatment plans with homogeneous dose distribution seem safer, especially in the ITV approach 👀

[Alper Kahvecioglu MD @kahvecioglu_a]

A never ending story ➡️ Central 🫁 SBRT

EORTC LungTech Trial (8x7.5 Gy)

❗️Severe late toxicity: 19.4% ❗️

~ 3x higher than the SUNSET by @drdavidpalma

What are the main differences between these trials and how can we improve the safety profile of SBRT?

https://t.co/JlDTYaM7rA

[Krishan Jethwa @KrishanJethwa]

🚨🚨🚨

Secondary analysis of GOG 258 suggests p53 status may be predictive (Yes! Not just prognostic) of response for advanced endometrial cancer

p53 WT associated with improved RFS when treated with chemotherapy + RT vs chemo alone.
@NRGonc

[Jeff Ryckman @jryckman3]

TACE vs. SBRT for HCC

TACE
🚫 📈 G3+ Toxicity.
🚫 Less cost-effective than RT, even if compared to carbon ions!
🚫 Invasive.
🚫Total ablation = the exception.
🚫LC ~40-50%.

SBRT
✅📉 G3+ Toxicity.
✅More cost-effective.
✅Non-invasive.
✅Total ablation = the rule.
✅ LC ~85%.